Article

WaveLight attains 20% of U.S. refractive laser sales in 1 year

New Orleans-WaveLight Inc. announced that during the last 12 months, its Allegretto Wave laser achieved a 20% share of all new refractive laser sales in the United States.

"We consider our success in the U.S. market to be our greatest accomplishment to date," said Max Reindl, chief executive officer of WaveLight Laser Technologie AG. "Ophthalmologists and patients alike benefit from the Allegretto Wave's shorter treatment times, safety features, and unique ablation profile designed to minimize the induction of spherical aberrations during surgery. Strong demand for the Allegretto Wave validates our commitment to develop and introduce the most innovative technology in the marketplace."

In addition to acquiring a considerable presence within ophthalmology, WaveLight recently announced that its revenues have increased 30% for the fiscal year ending July 31, 2004. WaveLight attributes much of its financial performance to refractive laser sales.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
© 2025 MJH Life Sciences

All rights reserved.